• NHL/ALL Immunotherapy Candidate Double Antibody YK012 Phase I Clinical Trial Completed First Subject Administration

    NHL/ALL免疫治疗候选双抗药物YK012 I期临床试验完成首例受试者给药 2023年5月24日,益科思特(北京)医药科技发展有限公司开发的用于治疗复发/难治性B细胞非霍奇金淋巴瘤的双特异性抗体药物YK012(CD3×CD19)I期临床研究在中国医学科学院肿瘤医院I期病房完成首例给药。当日上午9:40,YK012注射液通过微量注射泵及输注管路缓缓流入受试者体内,至给药后24h,受试者无

    2023/06/07 admin 31

  • NHL/ALL immunotherapy candidate dual antibody drug YK012 has officially entered the phase I clinical trial phase

    NHL/ALL免疫治疗候选双抗药物YK012 正式进入I期临床试验阶段2023年5月8日,益科思特(北京)医药科技发展有限公司开发的用于治疗复发性/难治性B细胞非霍奇金淋巴瘤的双特异性抗体药物YK012(CD3×CD19)I期临床研究在京正式启动。5月9日,首例受试者顺利签署知情同意书。中国医学科学院肿瘤医院临床研究中心副院长、肿瘤内科主任石远凯教授(左2),益科思特(北京)医药科技发

    2023/06/07 admin 10

  • Nature Major findings: lower affinity agonist antibody is more effective

    Nature重大发现:较低亲和力激动型抗体疗效更优长期以来,研究人员将高亲和力作为筛选治疗性抗体的关键标准。目前研究中的激动型抗体多数具有很高的亲和力,并且通过抗体的Fc功能进行交联,从而激活免疫细胞,但是这些抗体在临床中的疗效甚微,或具有较强的免疫不良反应。近日,Nature期刊上发表了题为“Reducing affinity as a strategy to boost immunomodul

    2023/03/02 admin 16

  • Phase I clinical trial project of YK012 for injection was officially launched

    After seven years of sharpening, the phase I clinical trial of YK012 for injection was officially launched recently.YK012 for injection is a new generation of safe, high-yield, long-acting and low-c

    2023/02/07 admin 41

  • The 2022 year-end summary meeting ended successfully

    On January 18, 2023, the 2022 year-end summary meeting of Ecotech (Beijing) Pharmaceutical Technology Development Co., Ltd. was held in the A101 conference room. All members of the company and the cha

    2023/01/10 admin 8

  • The leaders went to the Sino-Science Life Science Industrial Park for investigation

    In the afternoon of November 17, Meng Qingwu, Chairman of Yikester (Beijing) Pharmaceutical Technology Development Co., Ltd., and Qian Min, Chief Operating Officer, led a delegation to visit the Zhong

    2022/11/10 admin 10

Previous page12345Next page Go to No.